Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation
SUNNYVALE, Calif. – December 7, 2022 – (Newswire.com)
Riboscience, LLC, …
